Literature DB >> 18441382

Update of the drug resistance mutations in HIV-1: Spring 2008.

Victoria A Johnson1, Françoise Brun-Vezinet, Bonaventura Clotet, Huldrych F Günthard, Daniel R Kuritzkes, Deenan Pillay, Jonathan M Schapiro, Douglas D Richman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18441382     DOI： 10.1007/s11750-007-0034-z

Source DB:  PubMed          Journal:  Top HIV Med        ISSN： 1542-8826


× No keyword cloud information.
  64 in total

1.  Emerging trends of drug-resistant HIV-1 among drug-treated patients in former blood donors in Hubei, China: a three-year surveillance from 2004 to 2006.

Authors:  Jian Gong; Xiao-Qiong Wang; Xiao Tong; Xi-Hui Shen; Rong-Ge Yang
Journal:  Virol Sin       Date:  2011-12-10       Impact factor: 4.327

2.  Impact of HIV type 1 subtype on drug resistance mutations in Nigerian patients failing first-line therapy.

Authors:  B Chaplin; G Eisen; J Idoko; D Onwujekwe; E Idigbe; I Adewole; W Gashau; S Meloni; A D Sarr; J L Sankalé; E Ekong; R L Murphy; P Kanki
Journal:  AIDS Res Hum Retroviruses       Date:  2010-10-21       Impact factor: 2.205

3.  Short communication: antiretroviral therapy resistance mutations present in the HIV type 1 subtype C pol and env regions from therapy-naive patients in Zambia.

Authors:  Sandra Gonzalez; Clement Gondwe; Damien C Tully; Veenu Minhas; Danielle Shea; Chipepo Kankasa; Tendai M'soka; Charles Wood
Journal:  AIDS Res Hum Retroviruses       Date:  2010-07       Impact factor: 2.205

4.  Ultrasensitive detection of minor drug-resistant variants for HIV after nevirapine exposure using allele-specific PCR: clinical significance.

Authors:  Christopher F Rowley; Christian L Boutwell; Esther J Lee; Iain J MacLeod; Heather J Ribaudo; M Essex; Shahin Lockman
Journal:  AIDS Res Hum Retroviruses       Date:  2010-03       Impact factor: 2.205

5.  Transmitted HIV type 1 drug resistance among individuals with recent HIV infection in East and Southern Africa.

Authors:  Matt A Price; Carole L Wallis; Shabir Lakhi; Etienne Karita; Anatoli Kamali; Omu Anzala; Eduard J Sanders; Linda-Gail Bekker; Rogers Twesigye; Eric Hunter; Pontiano Kaleebu; Kayitesi Kayitenkore; Susan Allen; Eugene Ruzagira; Mary Mwangome; Gaudensia Mutua; Pauli N Amornkul; Gwynn Stevens; Sergei L K Pond; Malinda Schaefer; Mary A Papathanasopoulos; Wendy Stevens; Jill Gilmour
Journal:  AIDS Res Hum Retroviruses       Date:  2010-11-23       Impact factor: 2.205

6.  Both a protective and a deleterious role for the L76V mutation.

Authors:  Alessandra Tartaglia; Annalisa Saracino; Laura Monno; Carmine Tinelli; Gioacchino Angarano
Journal:  Antimicrob Agents Chemother       Date:  2009-04       Impact factor: 5.191

7.  Detecting and understanding combinatorial mutation patterns responsible for HIV drug resistance.

Authors:  Jing Zhang; Tingjun Hou; Wei Wang; Jun S Liu
Journal:  Proc Natl Acad Sci U S A       Date:  2010-01-11       Impact factor: 11.205

8.  Protease polymorphisms in HIV-1 subtype CRF01_AE represent selection by antiretroviral therapy and host immune pressure.

Authors:  Weerawat Manosuthi; David M Butler; Josué Pérez-Santiago; Art Fy Poon; Satish K Pillai; Sanjay R Mehta; Mary E Pacold; Douglas D Richman; Sergei Kosakovsky Pond; Davey M Smith
Journal:  AIDS       Date:  2010-01-28       Impact factor: 4.177

9.  The antiherpetic drug acyclovir inhibits HIV replication and selects the V75I reverse transcriptase multidrug resistance mutation.

Authors:  Moira A McMahon; Janet D Siliciano; Jun Lai; Jun O Liu; James T Stivers; Robert F Siliciano; Rahul M Kohli
Journal:  J Biol Chem       Date:  2008-09-24       Impact factor: 5.157

10.  Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy.

Authors:  Paul E Sax; Camlin Tierney; Ann C Collier; Margaret A Fischl; Katie Mollan; Lynne Peeples; Catherine Godfrey; Nasreen C Jahed; Laurie Myers; David Katzenstein; Awny Farajallah; James F Rooney; Belinda Ha; William C Woodward; Susan L Koletar; Victoria A Johnson; P Jan Geiseler; Eric S Daar
Journal:  N Engl J Med       Date:  2009-12-01       Impact factor: 91.245
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.